Eye Health & Tips

Ozempic ja nägemine: kuidas kaalulangus mõjutab silmi

31. märts 2026·Silvia Johanna Haavel·2 min

2024. one of the most talked-about topics in ophthalmology over the past year has been this: could Ozempic affect vision? This question did not emerge out of nowhere — it was prompted by clinical data that began accumulating in the FDA’s adverse event reporting database.

A detailed PMC study that reviewed 11,558 adverse event reports linked to semaglutide identified 417 cases involving visual disturbances and ischemic optic neuropathy (ION). The analysis suggests an important signal: compared with other diabetes medications, semaglutide users reported vision-related complaints up to four times more often.

What Is NAION and Why Does It Raise Concern?

NAION — non-arteritic anterior ischemic optic neuropathy — is a condition in which blood flow to the optic nerve becomes compromised. It can cause sudden, painless vision loss in one eye. Treatment options are limited.

According to the PMC analysis, during a 36-month follow-up period, NAION was diagnosed in 8.9% of diabetic patients receiving semaglutide treatment, compared with 1.8% among patients using alternative medications. Although the statistical difference is significant, it is important to emphasize that this was a retrospective association study and does not establish a direct causal relationship between the medication and the condition.

A study published in British Journal of Ophthalmology in March 2026 further found that users of Wegovy (the higher-dose semaglutide formulation) had up to a fivefold higher risk of ION compared with users of other GLP-1 medications. Among male users, the risk was nearly three times higher than among women.

A Causal Link Has Not Been Proven — But the Signal Is There

Dr. Ants Haavel of KSA Silmakeskus emphasizes:

“There is currently no conclusive evidence that semaglutide causes vision loss. However, these findings should not be ignored — especially given how widely these medications are used. Every patient starting a new course of treatment should undergo an eye examination to establish a baseline.”

This recommendation is particularly important for individuals who already have risk factors for eye disease, such as glaucoma, diabetic retinopathy, or high myopia. In these cases, regular eye check-ups are critically important.

What Patients Should Do

Although semaglutide has improved the quality of life for millions of patients, discontinuing treatment abruptly without medical guidance is not recommended. The integration of next-generation medications into everyday clinical practice should go hand in hand with regular ophthalmic monitoring to ensure comprehensive patient safety.

Symptoms that require immediate medical attention include sudden vision changes in one eye, loss of visual field, or persistent blurring that does not resolve. According to a 2024 analysis by The Ophthalmologist, Ozempic has become an increasingly common topic during eye care consultations — a positive sign that patients are asking more informed questions about their eye health.